Online Course

2017 CARE MOC Session 2 - Metabolic Bone Disease

Date:

Expires Oct 24, 2018

Program Information

CME: 3     MOC: 3

Assess your rheumatology medical knowledge and enhance your patient care. With 2017 CARE: MOC Session 2 - Metabolic Bone Disease you receive:

  • Nine case-based, multiple-choice questions with in-depth answer rationales
  • AMA PRA Category 1 Credits™ and 3 ABIM MOC points with a passing score of 70% or higher

Target Audience
This activity is designed for rheumatologists, physicians, and other healthcare providers who care for patients with rheumatic diseases.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Distinguish which patients need therapy for low bone mass
  • Determine which medications are not appropriate for treatment of selected patients with low bone mass
  • Evaluate patients with metabolic bone diseases other than osteoporosis
  • Describe the pathways that affect bone formation and resorption and the mechanism of action of osteoporosis drugs on that pathway

Registration Fees

Free for 2017 ACR/ARHP Annual Meeting attendees.*

*This online activity is intended for 2017 ACR/ARHP Annual Meeting Attendees only.

CME and MOC Information

Accreditation Statement
The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement 
The ACR designates this enduring material for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activities.

MOC Statement
Successful completion of this CME activity enables the participant to earn up to 3 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Claim MOC Points
See instructions on how to claim MOC points.

Needs Assessment
Rheumatologists certified in or after 1990 remain certified through American Board of Internal Medicine’s Maintenance of Certification (MOC) program. In addition to licensure and enrollment prerequisites, the MOC program requires that rheumatologists complete at least one MOC activity every two years, complete a total of 100 MOC points every 5 years, 20 of which must be in medical knowledge, and pass a MOC exam every ten years.

The ABIM MOC exam is designed to evaluate whether a board-certified rheumatologist has maintained competence and currency in the knowledge and judgment required for practice across the breadth of the discipline. The exam emphasizes diagnosis and management of prevalent conditions, particularly in areas where practice has changed in recent years. As a result of the blueprint review by ABIM diplomates in 2016, the MOC exam now focuses on situations in which physician intervention can have important consequences for patients. For conditions that are usually managed by other specialists, the focus will be on recognition rather than on management. Most questions describe patient scenarios and ask about the work done (that is, tasks performed) by physicians in the course of practice: diagnosis, testing, treatment/care decisions, risk assessment/prognosis/epidemiology, and pathophysiology/basic science.

In order to assist rheumatologists in fulfilling ABIM MOC and licensure renewal requirements and stay at the forefront of the profession the ACR develops a variety of online courses, including 2017 CARE MOC Sessions, to assist rheumatologists in assessing their rheumatology medical knowledge in the latest scientific developments and changes in practice in order to enhance their patient care.

Faculty and Disclosures

ACR Disclosure Statement
The ACR is an independent, professional organization that does not endorse specific procedures or products of any pharmaceutical/biotech concern. Educational activities provided by the ACR must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias.

Faculty participating in an ACR-sponsored activity must disclose to the editorial team and audience any financial or other relationship(s) including, but not limited to:

  1. Stock, stock options or bond holdings in a for-profit corporation or self-directed pension plan
  2. Research grants
  3. Employment (full or part-time)
  4. Ownership or partnership
  5. Consulting fees or other remuneration (payment)
  6. Non-remunerative positions of influence such as officer, board member, trustee or public spokesperson
  7. Receipt of royalties
  8. Speakers' bureau
  9. Other

The faculty reported the following disclosures.

  • Moderator: Allan C. Gelber, MD, PhD, MPH - No relevant financial relationships to disclose
  • Speaker: Chad L. Deal, MD – Amgen 5,7, Lilly 5,7
  • Question Author: Bethany A. Marston, MD - No relevant financial relationships to disclose

Additional Program Information

2017 Annual Meeting Live Session
Date: November 6, 12:30 PM - 2:00 PM
Location: ACR/ARHP Annual Meeting in San Diego, CA
Moderator: Allan C. Gelber, MD, PhD, MPH; Johns Hopkins University
Speaker: Chad L. Deal, MD; Cleveland Clinic Foundation
Question Author: Bethany A. Marston, MD; University of Rochester

About the Speaker 
Dr. Chad Deal is Head of the Center for Osteoporosis and Metabolic Bone Disease and a board-certified Rheumatologist at Cleveland Clinic. He has specialty interests in osteoporosis and related conditions. Dr. Deal did his undergraduate work at Washington University, St. Louis, Mo. He attended medical school at the University of Arkansas, was inducted into Alpha Omega Alpha, and graduated in 1977. His internship and residency were at Boston City Hospital in Boston, Mass. He completed a fellowship in arthritis and connective tissue diseases at Boston University School of Medicine in 1982. Dr. Deal has been in Cleveland since 1984. He was Associate Professor of Medicine at the Case Western Reserve University School of Medicine until 1999, when he left to become Head of the Center for Osteoporosis and Metabolic Bone Disease at Cleveland Clinic. Dr. Deal has been an active investigator in multiple clinical trials relating to arthritis and osteoporosis. He has been an investigator in numerous multicenter trials, including drug trials using teriparatide (PTH) with raloxifene, zoledronic acid after teriparatide, and novel anabolic agents. He is author of over 50 publications. He is a past member on the Committees on Rheumatologic Care, Training and Workforce, and Finance for the American College of Rheumatology. He is a member of the Interspecialty Medical Council of the NOF for the ACR. Dr. Deal is a reviewer for numerous rheumatology, orthopedic and osteoporosis journals. He has received the National Volunteer Service Citation from the Arthritis Foundation, and has been awarded Teacher of the Year in Rheumatic Diseases at Cleveland Clinic. He has been named one of the best doctors in Cleveland.

Contact Info / Inquiries

education@rheumatology.org
404-633-3777, ext. 381